Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_assertion type Assertion NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_head.
- NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_assertion description "[Neither the CYP2D6 10/10 genotype nor the CYP2C19 genotype is likely to have a clinically significant impact on prognosis, endometrial thickness, BMD, or total cholesterol levels in Japanese patients with breast cancer who are treated with adjuvant tamoxifen.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_provenance.
- NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_assertion evidence source_evidence_literature NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_provenance.
- NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_assertion SIO_000772 19156902 NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_provenance.
- NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_assertion wasDerivedFrom befree-20150227 NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_provenance.
- NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_assertion wasGeneratedBy ECO_0000203 NP341446.RAZBbiz_AJ2-5OoEWY4tea1OAnGA3VKEWDdckEhrJ3FRY130_provenance.